Results of an Interim Analysis of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of ZGN-1061 in Patients with Obesity and Type 2 Diabetes

被引：0
|
作者：
Kim, Terri
Zhuang, Dongliang
Hughes, Thomas E.
Kim, Dennis D.
Taylor, Kristin
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-105-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Results of an interimanalysis of a phase 2, randomised, double-blind, placebo-controlled clinical trial of ZGN-1061 in patients with obesity and type 2 diabetes
    Kim, T.
    Zhuang, D.
    Hughes, T. E.
    Kim, D. D.
    Taylor, K.
    DIABETOLOGIA, 2018, 61 : S326 - S326
  • [2] Final Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the MetAP2 Inhibitor ZGN-1061 in Patients with Type 2 Diabetes
    Kim, Terri
    Zhuang, Dongliang
    Haugen, Tonya L.
    Kim, Dennis D.
    Taylor, Kristin
    DIABETES, 2019, 68
  • [3] The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial
    Wentworth, John M.
    Colman, Peter G.
    DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1215 - 1219
  • [4] Creatine in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
    Gualano, Bruno
    Painneli, Vitor De Salles
    Roschel, Hamilton
    Artioli, Guilherme Giannini
    Neves, Manoel, Jr.
    De Sa Pinto, Ana Lucia
    Rossi Da Silva, Maria Elizabeth
    Cunha, Maria Rosaria
    Garcia Otaduy, Maria Concepcion
    Leite, Claudia Da Costa
    Ferreira, Julio Cesar
    Pereira, Rosa Maria
    Brum, Patricia Chakur
    Bonfa, Eloisa
    Lancha, Antonio Herbert, Jr.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2011, 43 (05): : 770 - 778
  • [5] Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Zhang, Bo
    Cheng, Zhifeng
    Chen, Ji
    Zhang, Xin
    Liu, Dexue
    Jiang, Hongwei
    Ma, Guoqing
    Wang, Xiaoyun
    Gan, Shenglian
    Sun, Juan
    Jin, Ping
    Yi, Jianjun
    Shi, Bimin
    Ma, Jianhua
    Ye, Shandong
    Wang, Guixia
    Ji, Linong
    Gu, Xuejiang
    Yu, Ting
    An, Pei
    Deng, Huan
    Li, Haoyu
    Li, Li
    Ma, Qingyang
    Qian, Lei
    Yang, Wenying
    DIABETES CARE, 2024, 47 (01) : 160 - 168
  • [6] Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial
    Ji, Linong
    Lu, Jinmiao
    Gao, Leili
    Ying, Changjiang
    Sun, Jiao
    Han, Jie
    Zhao, Wenhua
    Gao, Yunming
    Wang, Kun
    Zheng, Xin
    Xie, Daosheng
    Ding, Juping
    Zhao, Jiahong
    Yu, Qiang
    Wang, Tong
    DIABETES OBESITY & METABOLISM, 2023, 25 (12): : 3671 - 3681
  • [7] A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ANAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES
    Yang, H. K.
    Lee, S. H.
    Min, K. W.
    Park, S. W.
    Chung, C. H.
    Park, K. S.
    Choi, S. H.
    Song, K. -H.
    Kim, D. -M.
    Lee, M. -K.
    Sung, Y. A.
    Baik, S. H.
    Kim, I. J.
    Cha, B. -S.
    Park, J. H.
    Ahn, Y. B.
    Lee, I. -K.
    Yoo, S. -J.
    Kim, J. T.
    Park, I. B.
    Park, T. S.
    Yoon, K. -H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S149 - S150
  • [8] Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial
    Zhu, Dalong
    Li, Xiaoying
    Ma, Jianhua
    Zeng, Jiao'e
    Gan, Shenglian
    Dong, Xiaolin
    Yang, Jing
    Lin, Xiaohong
    Cai, Hanqing
    Song, Weihong
    Li, Xuefeng
    Zhang, Keqin
    Zhang, Qiu
    Lu, Yibing
    Bu, Ruifang
    Shao, Huige
    Wang, Guixia
    Yuan, Guoyue
    Ran, Xingwu
    Liao, Lin
    Zhao, Wenjuan
    Li, Ping
    Sun, Li
    Shi, Lixin
    Jiang, Zhaoshun
    Xue, Yaoming
    Jiang, Hongwei
    Li, Quanmin
    Li, Zongbao
    Fu, Maoxiong
    Liang, Zerong
    Guo, Lian
    Liu, Ming
    Xu, Chun
    Li, Wenhui
    Yu, Xuefeng
    Qin, Guijun
    Yang, Zhou
    Su, Benli
    Zeng, Longyi
    Geng, Houfa
    Shi, Yongquan
    Zhao, Yu
    Zhang, Yi
    Yang, Wenying
    Chen, Li
    NATURE MEDICINE, 2022, 28 (05) : 965 - +
  • [9] The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial
    Seyyedebrahimi, ShadiSadat
    Khodabandehloo, Hadi
    Esfahani, Ensieh Nasli
    Meshkani, Reza
    ACTA DIABETOLOGICA, 2018, 55 (04) : 341 - 353
  • [10] The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial
    ShadiSadat Seyyedebrahimi
    Hadi Khodabandehloo
    Ensieh Nasli Esfahani
    Reza Meshkani
    Acta Diabetologica, 2018, 55 : 341 - 353
12345